Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082277 · ClinicalTrials.gov registry record · Phase 4
Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 237
- Enrollment target
NCT00082277 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 237 participants.
The verdict
NCT00082277, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 237 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety parameters of anastrozole with regard to its potential effects on postmenopausal bone loss and on lipid profiles. This trial is conducted to investigate the effects of risedronate on BMD and on bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone-receptor-positive early breast cancer and who are high or moderate risk of fragility fracture. It is also conducted to determine the effects of anastrozole on bone mineral density (BMD) and on bone metabolism in women at low risk of fragility fracture.
Interventions
- DRUG Anastrozole
- DRUG Risedronate Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082277
The ClinicalTrials.gov registry entry for NCT00082277 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anastrozole is the first listed.
NCT00082277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082277 about?
NCT00082277 is a clinical study titled "Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer". The purpose of this study is to evaluate safety parameters of anastrozole with regard to its potential effects on postmenopausal bone loss and on lipid profiles. This trial is conducted to investigate the effects of risedronate on BMD and on bone metabolism in postmenopausal women using anastrozole ...
What is the current status of trial NCT00082277?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 237 participants. The study started on 2004-04. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00082277?
The interventions under investigation include: Anastrozole (DRUG), Risedronate Sodium (DRUG).
Who is sponsoring clinical trial NCT00082277?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.